Olympus Corporation of the Americas recalled 1,007 bronchofiberscopes on September 11, 2025, due to safety concerns related to their use with laser and high-frequency therapy equipment. The recall affects devices distributed nationwide in the U.S. and involves additional instructions for safe use.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
The recall involves the OES Bronchofiberscope Olympus BF Type P60, Model No. BF-P60. A total of 1,007 units are recalled in the U.S., with an additional 5,443 units affected worldwide. The devices were distributed nationwide.
The recall addresses safety concerns when using bronchoscopes in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment. The updates clarify instructions for effective and safe use.
No specific incidents or injuries have been reported related to this recall. The recall is classified as Class I, indicating a high hazard level.
Stop using the device immediately. Healthcare providers and patients should follow the manufacturer's recall instructions. Contact Olympus Corporation of the Americas for further guidance.
For more information, contact Olympus Corporation of the Americas. Visit their website or call for additional assistance.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.